Objective-In diabetics, hyperglycemia results in deficient endothelial progenitors and cells, leading to cardiovascular complications. We aim to engineer 3-dimensional (3D) vascular networks in synthetic hydrogels from type 1 diabetes mellitus (T1D) patient-derived human-induced pluripotent stem cells (hiPSCs), to serve as a transformative autologous vascular therapy for diabetic patients. Approach and Results-We validated and optimized an adherent, feeder-free differentiation procedure to derive early vascular cells (EVCs) with high portions of vascular endothelial cadherin-positive cells from hiPSCs. We demonstrate similar differentiation efficiency from hiPSCs derived from healthy donor and patients with T1D. T1D-hiPSC-derived vascular endothelial cadherin-positive cells can mature to functional endothelial cells-expressing mature markers: von Willebrand factor and endothelial nitric oxide synthase are capable of lectin binding and acetylated low-density lipoprotein uptake, form cords in Matrigel and respond to tumor necrosis factor-α. When embedded in engineered hyaluronic acid hydrogels, T1D-EVCs undergo morphogenesis and assemble into 3D networks. When encapsulated in a novel hypoxiainducible hydrogel, T1D-EVCs respond to low oxygen and form 3D networks. As xenografts, T1D-EVCs incorporate into developing zebrafish vasculature. Conclusions-Using our robust protocol, we can direct efficient differentiation of T1D-hiPSC to EVCs. Early endothelial cells derived from T1D-hiPSC are functional when mature. T1D-EVCs self-assembled into 3D networks when embedded in hyaluronic acid and hypoxia-inducible hydrogels. The capability of T1D-EVCs to assemble into 3D networks in engineered matrices and to respond to a hypoxic microenvironment is a significant advancement for autologous vascular therapy in diabetic patients and has broad importance for tissue engineering. (Arterioscler Thromb Vasc Biol. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
C ardiovascular diseases (CVDs) are currently a leading cause of death in the United States. 1 Studies have demonstrated that because of hyperglycemia, patients with diabetes mellitus have a higher risk in developing CVD. 2, 3 Under prolong hyperglycemia conditions, physiological changes in diabetic patients cause aberrant angiogenesis in both micro and macro vasculatures, resulting in CVD such as coronary heart disease and peripheral arterial disease. 4, 5 High blood glucose also impairs endothelial progenitor cell (EPC) functionality and causes poor neovascularization in response to hypoxia, directly affecting wound healing processes in diabetic patients. 6, 7 Thus, generation of vasculatures holds great promise in treating diabetic patients with CVD and wound healing complications. [8] [9] [10] Stem cells, defined by their ability to self-renew and differentiate into multiple mature cell types, are emerging as a promising source for noninvasive approaches to tissue regeneration, including vascular regeneration. 11 Autologous vascular stem cell therapy could contribute as a potential source for endothelial cells (ECs) to treat CVD. One such example would be endogenous EPCs. Both animal and clinical studies have demonstrated that EPCs can be isolated, expanded in vitro and transplanted to improve revascularization in ischemic CVD. [12] [13] [14] [15] Theoretically, EPCs represent as a great candidate for vascular therapy. Unfortunately, the functions of EPCs are compromised under high glucose conditions in diabetes mellitus. [16] [17] [18] An alternate source of stem cells for vascular therapy is human-induced pluripotent stem cells (hiPSCs). The discovery of the hiPSCs 19, 20 makes stem cell therapy particularly attractive for individuals with diabetes mellitus offering not only an autologous therapy approach but also the potential of reversing the stress effects of high glucose, caused by diabetes mellitus, in reprogrammed hiPSCs. 21 Thus, hiPSCs may provide a renewable stem cell source for diabetic patients, which could improve wound healing outcomes. December 2015
In previous work, we established a step-wise differentiation scheme to generate a bicellular population of early vascular cells (EVCs) consisting of vascular endothelial cadherin-positive (VEcad + ) cells (early ECs) and platelet-derived growth factor β-positive (PDGFRβ + ) cells (early pericytes) from healthy hiPSC lines. EVCs can be further differentiated to mature ECs or pericytes. When encapsulated in a synthetic hyaluronic acid (HA) hydrogel, EVCs self-assemble to functional 3-dimensional (3D) vascular networks. 8 In this study, using the same differentiation scheme, we investigated if EVCs can be derived from type I diabetes mellitus (T1D) patientderived hiPSCs, matured into functional ECs and assembled into vascular networks in synthetic hydrogel in response to hypoxic conditions. We examined the differentiation of T1D-hiPSCs to EVCs, further increased the portion of VEcad + cells in the EVCs and whether the T1D-EVCs can be matured to functional ECs. We next determined the ability of T1D-EVCs encapsulated in a synthetic HA hydrogel to undergo morphogenesis and self-organize to form 3D vascular networks. We also examined the ability of T1D-EVCs to undergo morphogenesis to form 3D vascular networks in response to hypoxic conditions using a novel hypoxia-inducible (HI) hydrogel. Finally, we demonstrated the in vivo functionality of T1D-EVCs using a zebrafish xenograft model. This work shows that T1D-hiPSCs can differentiate into EVCs, mature into functional ECs, generate vascular networks in deliverable hydrogel as a response to hypoxia and integrate into host vasculature networks in vivo. Overall, this approach provides us a unique opportunity to advance autologous therapy for diabetic vascular complications, especially diabetic wound healing.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Validation and Optimization of EVC Differentiation From hiPSCs
In previous works, we established a 2 step, adherent culture protocol for the controlled differentiation of human embryonic stem cells and healthy hiPSCs into a bicellular EVC population. 8, 22, 23 During the first 6 days of differentiation, seeded single-cell hiP-SCs were induced to become mesodermal. On reseeding on day 6, they proceed to differentiate into EVCs for another 6 days ( Figure  IA in the online-only Data Supplement). This EVC population consists of VEcad + early ECs and PDGFRβ + early pericytes. With our goal to develop a therapeutic solution for diabeticrelated vascular complications, we first sought to demonstrate EVC differentiation from T1D-hiPSCs and to increase the EC yield in our EVC cultures. We reasoned that higher EC yield will more closely mimic the in vivo EC to pericyte ratio in the average microvessel. 24 In the optimization process, we used healthy individual-derived BC1-hiPSC, a completely sequenced hiPSC cell line-derived via nonviral reprogramming techniques. 8, 25, 26 It was previously shown that the addition of the Rho-associated coiled coil-containing kinases (ROCKs) inhibitor Y27632 improves the survival of the single-cell hiPSCs. 27 Another study demonstrated that the initial cell-seeding density affects the differentiation efficiency of pancreatic endocrine cells. 28 Thus, as a comparison with our original culture conditions (5×10 4 cells/cm 2 ; control), we supplemented the differentiation media with ROCK inhibitor Y27632 (5×10 4 cells/cm 2 +RI) and also tested higher density culture conditions by increasing cell-seeding density to 1×10 5 cells/ cm 2 ( Figure IA in the online-only Data Supplement). On day 1, cultures seeded at a higher density, 1×10 5 cells/cm 2 , resulted in an overall increase in total cell attachment ( Figure IBi Figure IC in the onlineonly Data Supplement). By increasing cell-seeding density from 5×10 4 cells/cm 2 to 1×10 5 cells/cm 2 , there was a 2-fold increase in total cell attachment ( Figure IC in the online-only Data Supplement). On day 12 of differentiation, cells in culture using the original low-density protocol (control) were not confluent and appeared mostly elongated and spindle like ( Figure IDi in the online-only Data Supplement). On the contrary, cells seeded either at a higher density or with ROCK inhibitor appeared as patches of cobblestone-like cells surrounded by cells that are spindle like and elongated ( Figure IDii and IDiii in the onlineonly Data Supplement, respectively). Importantly, we found an increased total yield of VEcad + cells in the modified differentiation protocols. The total yield of VEcad + cells for ROCK inhibitor supplemented differentiation is 41.76±17.05% (n=3) and for high initial cell-seeding density is 62.0.0±14.9% (n=6) compared with our original protocol, which yielded 18.9±14.9% VEcad + cells (n=4; Figure IE in the online-only Data Supplement).
EVC Differentiation From T1D Patient-Derived hiPSC
We examined whether hiPSCs derived from patients with vascular complications have a similar differentiation Nonstandard Abbreviations and Acronyms 3D 3-dimensional potential to BC1-hiPSC derived from a healthy donor. Here, we used 2 T1D patient-derived hiPSC lines, H2.1 and 1018S, to generate a bicellular population of EVCs. [29] [30] [31] We compared the original differentiation protocol and the improved differentiation protocols focusing on supplementation with ROCK inhibitor. Similar to the BC1-hiPSC, in comparison with cultures without ROCK inhibitor addition ( Figure  1Ai ), the ROCK inhibitor supplemented cells attached better and had a morphology that is more relaxed and less spindle like on day 1 (Figure 1Aii ; Figure 
EC Maturation of T1D-EVCs
We next examined the endothelial maturation and functionality potential of T1D-EVCs. We speculated that VEcad + cells derived from T1D-hiPSCs can mature into normally functional ECs. VEcad + cells were sorted using magnetic sorting and purification of >90% VEcad expression of the sorted cells was confirmed using flow cytometry (Figure 2A ). Sorted VEcad + cells were subcultured and expanded for another 6 days, in which they maintained the cobblestone morphology of typical ECs ( Figure 2B ), compared with VEcad − cells, where most cells appeared fibroblast like ( Figure 2B ). Sorted ECs exhibited typical membrane expression of VEcad and CD31 as well as cytoplasmic punctate expression of von Willebrand factor and cytoplasmic endothelial nitric oxide synthase-both mature EC markers. Sorted cells demonstrated the ability to bind to lectin Ulex europaeus, uptake acetylated low-density lipoprotein ( Figure 2C ) and form cord when seeded on top of Matrigel ( Figure 2D ). In addition, T1D-EVCs responded to the inflammatory cytokine, tumor necrosis factor-α by upregulating expression of intercellular adhesion molecule 1 ( Figure 2E ). Overall, T1D-EVCs exhibit mature endothelial characteristics consistent with ECs derived from healthy BC1-hiPSC control cultures. 7
Vascular Assembly of T1D-EVCs in HA Hydrogels
To assess the potential of T1D-EVCs to self-assemble into a microvascular bed, we examined network formation in a synthetic HA-based hydrogel. These engineered HA hydrogels present adhesion and degradation motifs, allowing sequential progression in vascular morphogenesis. 8, 32 We tracked the process of T1D-EVCs network formation every day for a total of 3 days. During the first 2 days after encapsulation of T1D-EVCs in HA-based hydrogels, we observed vacuole formation in many of the cells, presumably early ECs ( Figure IVA in the online-only Data Supplement). In some cases, larger lumen formed when multiple vacuoles merged and coalesced into a larger structure ( Figure IVAiii and IVAiv in the online-only Data Supplement). Within the same time frame, we also observed tubulogenesis, in which many of the cells have sprouted. On day 3, an extensive, multicellular network was observed within the hydrogel, which seems to be a complex vascular network ( Figure IVB and IVC in the online-only Data Supplement). Lumens were detected within the 3D vascular networks ( Figure IVD in the online-only Data Supplement). By tracking the progression of 3D network formation of encapsulated T1D-EVCs, we observed cellular behavior and network progression that resembles typical vascular morphogenesis. 33 Overall, we demonstrated that T1D-EVCs are able to self-assemble into vascular networks in a synthetic hydrogel.
Three-Dimensional T1D-EVC Network Formation in HI Hydrogel
Because EPC-mediated blood vessel formation in diabetic patients is deficient in response to hypoxia, 34 we sought to determine if T1D-EVCs retain similar deficits. We used a novel HI hydrogel system developed in our laboratory 35 to encapsulate T1D-EVCs and examined their responsiveness to a hypoxic microenvironment, similar to diabetic wounds. Our positive control was healthy BC1-EVCs. 8, 23 EVC derivatives were encapsulated in either nonhypoxic or hypoxic hydrogel (Materials and Methods section of this article), and the process of morphogenesis and network formation was tracked every 24 hours for a total of 3 days. During the encapsulation period, we recorded dissolved oxygen (DO) levels of EVCs encapsulated in the hypoxic and nonhypoxic hydrogel at a range of 0.1% to 5.0% and 10% to 15%, respectively for the first 24 hours ( Figure VA and VB in the online-only Data Supplement). We found that in the hypoxic hydrogel, EVCs progressed through all stages of vascular morphogenesis, starting from the formation of individual vacuoles that coalesce to form lumens in the first day ( Figure VIAi 
Three-Dimensional Analysis of T1D-EVC Hypoxic Networks
Vascular network quantification is typically performed on 2D projections of 3D confocal z stacks, limiting information along the z axis. To have a more comprehensive analysis of the 3D T1D-EVC hypoxic networks formed in hydrogels, we used 3D image analysis. This approach enabled quantification of the differences between vascular networks formed within nonhypoxic and hypoxic encapsulated control BC1-EVCs ( Figure VII in the online-only Data Supplement) and T1D-EVCs (Figure 3 ; Movie SI in the online-only Data Supplement). On the basis of the analysis, we observed significant differences between the nonhypoxic and hypoxic hydrogel encapsulated T1D-EVCs, especially along the z axis. At the same cell encapsulation density and after 3 days in culture, the total combined tube length of the hypoxic hydrogel encapsulated T1D-EVC network is 4× longer than its nonhypoxic counterpart ( Figure 3C ), a slightly larger difference when compared with the control-EVCs ( Figure VIIC in the onlineonly Data Supplement). In control-EVC hypoxic hydrogels, the length of tubes ranges from 10 to 3600 μm, compared with 10 to 900 μm in nonhypoxic condition ( Figure VIID in the online-only Data Supplement). In T1D-EVC hypoxic hydrogel constructs, the individual continuous tube length ranges from 10 to 3000 μm, in comparison with 10 to 200 μm in the nonhypoxic hydrogel constructs ( Figure 3D) . Also, the mean tube thickness of T1D-EVC nonhypoxic hydrogel construct is ≈1-μm thicker in diameter than the T1D-EVC hypoxic hydrogel construct ( Figure 3E ), similar to the case of BC1-EVCs ( Figure VIIE in the online-only Data Supplement). A unique aspect of 3D analysis is that it provides information of the T1D-EVC network in the Z direction. One astounding effect of hypoxic hydrogels on T1D-EVCs tubulogenesis and network formation is that the network structures span a much larger distance along the z axis, ≈6× larger than those in the nonhypoxic hydrogel ( Figure 3F) . Surprisingly, the BC1-EVC networks in hypoxic hydrogel spanned an average Z distance that is only slightly larger than the network in the nonhypoxic hydrogel ( Figure VIIF in the online-only Data Supplement). The total volume covered by T1D-EVC networks in hypoxic hydrogels is 2.5×10 6 μm 3 , twice the volume of T1D-EVC networks in nonhypoxic hydrogel ( Figure 3G and 3H) , and is consistent with BC1-EVC networks ( Figure VIIG -VIIH in the online-only Data Supplement). This indicates that T1D-EVCs are responding to low dissolved oxygen levels, which plays a role in stimulating the migratory behavior and ability to form networks in hypoxic hydrogel, similar to the control cells. In nonhypoxic hydrogels, most T1D-EVC tubes form along the x-y axis, instead of the z axis, indicating a lack of stimulation and signaling for migratory behaviors of EVCs.
In Vivo Functionality of T1D-EVCs in Zebrafish
To further assess the functionality of T1D-EVCs, we used a zebrafish xenograft model. 36 T1D-EVCs were injected into 2-day post fertilization embryos via the duct of Cuvier and their integration with the developing host vasculature was determined. The percentage of vessel incorporation was examined and analyzed at 5-day postinjection using Imaris (see Materials and Methods; Figure VIII in the online-only Data Supplement). On average, 50.95±12.23% of the injected T1D-EVCs are incorporated into the developing zebrafish vasculature ( Figure 4A and 4B) . We found 71.88% of the incorporation located in the trunk of the embryo and 28.12% in the head region ( Figure 4C ). These observations demonstrate in vivo functionality of T1D-EVCs, by incorporating into the vessels of the developing zebrafish.
Discussion
Patients with diabetes mellitus had serious chronic health complications as a result of prolonged exposure to high blood glucose levels. Because most of these complications are related to dysfunction of ECs and EPCs in these patients, an ideal solution would be an alternative source of adult stem cells (other than the EPCs) for potential autologous vascular therapy. Studies have shown that coculturing ECs with murine pericytes or human mesenchymal stem cells is important in sustaining engineered blood vessel network in vivo. [37] [38] [39] [40] In this study, we successfully described the first example of cultured EVC differentiation, consisting of VEcad + cells (early ECs) and PDGFRβ + cells (early pericytes), from T1D patientderived hiPSCs.
In an attempt to increase the number of VEcad + cells in EVC cultures, we discovered beneficial effects from increasing initial cell-seeding density and of ROCK inhibition from both healthy and diabetic hiPSCs. Cell-seeding density has been an important factor in stem cell cultures about maintaining cells in a differentiated state, 41 or in differentiating adult stem cells or iPSCs into a specific cell type. 28, 42 For example, it has been shown that the differentiation propensity of human embryonic stem cells into pancreatic endocrine cells is favored at a high initial seeding density of 5.3×10 4 cells/ cm 2 , which reached 100% confluency 24 hours after seeding. 28 This seems to be the case for our EVC differentiation protocol where increased initial seeding density from 5×10 4 cells/ cm 2 to 1×10 5 cells/cm 2 provided us with a significant increase of early EC yield. Similar observations apply to our differentiation culture supplemented with a ROCK inhibitor. ROCK inhibition improved the cell survival and cell attachment during seeding, 27, 43 in turn, creating an effect that is similar to increasing the initial seeding density by providing a better EC yield during differentiation. It is also plausible that ROCK inhibition plays a role beyond simply increasing plating efficiency and cell survival in culture. For instance, phosphatase and tensin homolog is activated by the Rho/ROCK pathway, which leads to inhibition of the protein kinase B (also known as Akt) pathway, which regulates cell proliferation, specifically EC proliferation. [44] [45] [46] [47] [48] However, activation of myosin light chain by Rho/ROCK pathway is known to promote myogenic differentiation, including pericyte differentiation. 44, 49, 50 Thus, it is possible that suppression of ROCK in our differentiation culture plays a role in inducing EC fates. Ongoing studies are being performed to dissect the underlying mechanism of the ROCK pathway in EC differentiation before drawing any conclusion. Importantly, we found that both T1D-hiPSC lines examined here, which were reprogrammed in 2 different laboratories using different approaches, 29, 30 show comparable EVC differentiation efficiency and capability to mature to functional ECs, similar to the healthy BC1-hiPSCs.
Because ECs and EPCs isolated from diabetic patients are known to be deficient because of exposure to hyperglycemia, [16] [17] [18] we investigated if T1D-hiPSCs retain any deficits typical of diabetic ECs. Thus, we addressed the question by assessing whether T1D-derived ECs express mature EC markers and behaved as healthy ECs using functional assays, such as Matrigel cord formation and tumor necrosis factor-α responsiveness. We found that T1D-ECs expressed mature endothelial markers and displayed behaviors typical of mature and functional ECs, as in the case of BC1-ECs. 8 One main advantage of deriving both ECs and pericytes from the same source is that the differentiated EVCs are readily available for coencapsulation in synthetic hydrogels to form stable 3D vascular networks. 8, 32 Using 2 different synthetic hydrogel systems, we demonstrated that the T1D-EVCs are capable for forming 3D networks on encapsulation, paving the way for future research toward potential translational and therapeutic purposes.
Similar to BC1-hiPSC-derived EVCs, bicellular EVC populations derived from T1D-hiPSC formed 3D microvascular networks when embedded in engineered HA-based hydrogel. 8 We observed vacuole formation, coalescing of vacuoles to form bigger lumens and sprouting of the T1D-EVCs during the first 2 days of encapsulation. Eventually, in the next stage of vascular morphogenesis, microvascular networks formed with cell sprouting and tubules joining between neighboring cells. Overall, the kinetics of morphogenesis was found to be similar between the HA-embedded T1D-EVCs and BC1-EVCs as previously described. 8 This finding is encouraging as it indicates that T1D-EVCs respond to cues from the surrounding extracellular matrix to form complex 3D vascular networks.
To further validate the functionality of the T1D-EVCs, we used a novel hypoxic hydrogel system established in our laboratory. 35 We demonstrated that T1D-EVCs, like endothelial progenitors 35 and healthy BC1-EVCs, responded to low dissolved oxygen level in the HI hydrogel, by undergoing vascular morphogenesis to form 3D EVC networks. The observed mean tube length and thickness of T1D-EVCs encapsulated in hypoxic hydrogel are comparable with those of hypoxic hydrogel encapsulated endothelial progenitors 35 and BC1-EVCs. In our previous study, we found that accumulation of HI factors 1α and 2α activates MT1-MMP, which enables vascular morphogenesis of EPCs within the hypoxic hydrogel. 35 As activation of 3D vascular morphogenesis is similar in EPCs and hiPSC-EVCs, 8, 32 it is safe to speculate that hiPSC-EVC morphogenesis in the hypoxic hydrogels follows the same mechanism as in EPCs.
Altogether, these observations demonstrate that T1D-EVCs are sensitive and responsive to a hypoxic microenvironment. In addition, by inducing hypoxia, the hypoxic hydrogel provides a platform for guiding and accelerating 3D EVC network formation in vitro. To our knowledge, this is the first time that the formation of EVC network in response to hypoxic microenvironment has been realized. Overall, this finding demonstrates the ability of T1D-EVCs to respond to a hypoxic matrix to form 3D networks, which may lead to a therapeutic tool to treat diabetic vascular complications, such as diabetic foot ulcers. Endothelial progenitors are limited in function and in number in diabetic patients, 51, 52 exacerbating vascular complications, such as neovascularization in diabetic wounds. Shortened healing period of diabetic foot ulcers have been demonstrated to decrease chances of amputation. 53 Thus, the combined approach of direct and controlled vascular differentiation and delivery of a microvascular bed in hydrogel matrix could potentially promote and accelerate wound healing in complications, such as diabetic foot ulcers. 
